Today: 19 January 2026
Subscribe
Browse Category

Clinical Trials News 12 January 2026 - 18 January 2026

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two…
18 January 2026
····
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent…
18 January 2026
····
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

NEW YORK, Jan 18, 2026, 05:13 EST — Market closed ImmunityBio shares jumped sharply on Friday following a series of updates, including early sales figures for its approved bladder-cancer drug and new data from its development pipeline. The stock closed the day up 39.75% at $5.52 and later climbed to $6.04 in after-hours trading. (Yahoo Finance) This move is significant…
18 January 2026
···
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

New York, Jan 17, 2026, 08:04 ET — Market closed. ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments. (Nasdaq) Why this matters now: these updates offer traders new…
17 January 2026
····
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

New York, Jan 16, 2026, 20:14 EST — Market closed AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement. (Investing) The readout arrives at a tough time for bulls. AbbVie is hustling to keep…
17 January 2026
···
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

New York, Jan 16, 2026, 14:14 ET — Regular session AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant…
16 January 2026
····
Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

New York, Jan 15, 2026, 11:01 ET — Regular session Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report. This update is crucial as Johnson & Johnson aims to expand the footprint of its newer drugs while shielding established products from pricing cuts and…
15 January 2026
····
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

New York, Jan 14, 2026, 18:15 EST — After-hours Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli. Investors are zeroing in on Johnson & Johnson’s drug pipeline for the next growth phase as the company gears up for its quarterly report next week. Oncology…
15 January 2026
····
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

New York, Jan 14, 2026, 12:55 (EST) — Regular session Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline. The move matters because Edgewise is still pre-commercial, and its valuation hangs…
14 January 2026
····
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it…
14 January 2026
····
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

New York, Jan 12, 2026, 14:55 EST — Regular session Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab. (Smmttx) Summit’s filing marks its first attempt to introduce ivonescimab to…
12 January 2026
···
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

New York, January 11, 2026, 19:47 ET — The market has closed. CG Oncology shares jumped 29.3% to close at $54.20 on Friday, hitting a session high of $57.40 amid increased interest ahead of a critical bladder-cancer readout. Trading volume came in around 7.0 million shares. (Streetinsider) This shift is significant since CG Oncology, a clinical-stage biotech, usually sees its…
12 January 2026
····
1 2 3 … 8

Stock Market Today

  • KeyCorp Announces $0.205 Dividend with Cautious Outlook on Sustainability
    January 19, 2026, 8:07 AM EST. KeyCorp (NYSE:KEY) will pay a dividend of $0.205 per share on March 13, representing a 3.9% yield above the industry average. The bank has a decade-long history of dividend payments, growing at 11% annually from $0.30 in 2016 to $0.82 recently. However, its payout ratio is high at 94%, raising concerns about sustainability despite forecasted earnings per share growth of 147% over three years and an expected payout ratio drop to 43%. Earnings have declined 5.7% annually over five years, adding to uncertainty. Analysts urge caution as KeyCorp's dividend payments may be challenging to maintain, though past consistency offers some reassurance.
Go toTop